Status:
RECRUITING
Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Lung Cancer
Eligibility:
All Genders
20+ years
Brief Summary
The investigators aim to identify novel circulating methylated biomarkers for early lung cancer detection as well as to develop new technologies that are clinically applicable with high sensitivity an...
Detailed Description
Lung cancer is the leading cause of cancer death, accounting for 2.09 million cases in 2018 worldwide. There is a huge demand globally for sensitive and reliable assays to intercept lung cancer at ear...
Eligibility Criteria
Inclusion
- Subjects suspected or confirmed diagnosis of lung cancer.
- Subjects who had indeterminate sub-centimeter pulmonary nodules or ground glass opacities discovered by computed tomography.
- Non-cancer subjects: including healthy volunteers and chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
- Subjects age over 20.
Exclusion
- Pregnancy.
- Subjects with HIV infection.
- Unable to or unwilling to give informed consent.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT04814407
Start Date
March 1 2021
End Date
December 31 2027
Last Update
June 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100225